A randomized pilot study of aortic waveform guided therapy in chronic heart failure
Barry A Borlaug1, Thomas P Olson, Sahar S Abdelmoneim
1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Journal of the American Heart Association
|March 22, 2014
Summary
Aortic pressure-guided treatment improved exercise capacity in heart failure patients beyond standard therapy. This approach, using central aortic pressure, enhances medication titration for better outcomes in heart failure management.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Pharmacology
Background:
- Current heart failure (HF) treatment relies on brachial artery pressure, which is less accurate than central aortic pressure for assessing ventricular afterload.
- Ventricular afterload significantly impacts cardiovascular function and disease progression in heart failure patients.
- Optimizing medication titration beyond standard goal-directed therapy (GDMT) is crucial for improving HF outcomes.
Purpose of the Study:
- To investigate if aggressive vasoactive medication titration guided by central aortic pressure improves exercise capacity in HF.
- To determine the effect of aortic pressure-guided therapy on cardiovascular structure and function in HF patients.
- To compare aortic pressure-guided treatment with conventional therapy in chronic heart failure.
Main Methods:
- Fifty chronic heart failure patients underwent cardiopulmonary exercise testing, echocardiography, and arterial tonometry.
- Patients were randomized to either aortic pressure-guided treatment (n=23) or conventional therapy (n=27) after GDMT optimization.
- Aortic pressure-guided treatment aimed to reduce aortic augmentation index to 0%, while conventional therapy focused on brachial pressure.
Main Results:
- The aortic pressure-guided group showed significantly greater improvement in peak oxygen consumption compared to controls (P=0.025).
- While reductions in aortic augmentation index were similar between groups, forward stroke volume increased and arterial elastance/left ventricular volumes decreased in all participants.
- Patients in the active treatment group received more additional vasoactive therapies without increased risk of hypotension or renal function decline.
Conclusions:
- Maximizing GDMT in heart failure patients can improve afterload reduction and reverse cardiac remodeling.
- Titrating medications based on central aortic pressure data significantly enhances exercise capacity in heart failure patients.
- Aortic pressure-guided therapy represents a promising strategy for improving functional outcomes in heart failure management.
